Text Size

Molecular imaging reveals unique degenerative changes in experimental glaucoma

Lmamura K., Onoe H., Shimazawa M., Nozaki S., Wada Y., Kato K., Nakajima H., Mizuma H., Onoe K., Taniguchi T., Sasaoka M., Hara H., Tanaka S., Araie M., Watanabe Y.

  • 2009
  • NeuroReport
View publication
  • Therapeutic Area


  • Categories

    Preclinical development

  • Affiliations

    Department of Systems Life Engineering, Maebashi Institute of Technology, Maebashi-shi, Japan; Department of Physiology, Osaka City University Graduate, School of Medicine, Osaka, Japan; Laboratory of Visual Neurocomputing, Brain Science Institute, RIKEN, Saitama, Japan; Molecular Imaging Research Program, RIKEN, Kobe, Japan; Department of Biofunctional Evaluation, Molecular Pharmacology, Gifu Pharmaceutical University, Mitahora-higashi, Gifu, Japan; Glaucoma Group, Research and Development Center, Santen Pharmaceutical Co. Ltd., Ikoma, Japan; Department of Ophthalmology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Department of Systems Life Engineering, Maebashi Institute of Technology, 460-1 Kamisadori-machi, Maebashi-shi, Gunma 371-0816, Japan

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022